Tenax Therapeutics (NASDAQ:TENX) Posts Quarterly Earnings Results, Misses Estimates By $0.46 EPS

Tenax Therapeutics (NASDAQ:TENX) released its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.46), Fidelity Earnings reports.

NASDAQ:TENX traded up $0.01 during trading hours on Thursday, hitting $1.91. The stock had a trading volume of 200 shares, compared to its average volume of 1,488,208. The company has a 50 day simple moving average of $2.29 and a two-hundred day simple moving average of $1.67. The firm has a market capitalization of $24.10 million, a price-to-earnings ratio of -1.57 and a beta of 2.46. Tenax Therapeutics has a one year low of $0.51 and a one year high of $3.68.

Separately, HC Wainwright started coverage on Tenax Therapeutics in a research report on Tuesday, December 29th. They set a “buy” rating and a $5.00 price target on the stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing low cardiac output syndrome.

Further Reading: NASDAQ Stock Market Explained

Earnings History for Tenax Therapeutics (NASDAQ:TENX)

Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.